AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases
- Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalities
- Integrating its precision medicine approach, AC Immune is advancing three clinical-stage vaccines targeting Tau, Abeta and α-synuclein
- Precisely targeted active immunotherapy may enable prevention of pathological pathways before the occurrence of irreversible neuronal damage
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today hosted key opinion leader (KOL) Cynthia A. Lemere, Ph.D., of the Ann Romney Center for Neurologic Diseases at Brigham & Women’s Hospital and Harvard Medical School, Boston, for a webinar focused on vaccines to treat and prevent Alzheimer’s and Parkinson’s diseases.